These peptides work through entirely different biological pathways, and understanding those differences is the key to optimizing your protocol
Do you ship the BPC-157 peptide to all Canadian provinces
and for those EGRIFTAtreated patients completing the 26-week treatment period that were re-randomized to EGRIFTA (T-T group) or re-randomized to placebo, 37% and 32%, respectively, had impaired glucose tolerance, while 2% rerandomized to EGRIFTA and 6% re-randomized to placebo had diet-controlled type 2 diabetes mellitus
Advanced protocols with the 60 mg vial Beyond standard titration, the 60 mg vial supports several advanced dosing strategies that smaller vials cannot practically accommodate
Patients undergo cyclophosphamide therapy every three to four weeks, with the frequency of administration determined by the physician and based on the severity of the patients illness
Prescription is only available after consultation with a licensed provider to determine if treatment is appropriate.
